Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Self-Concept and Autobiographical Memory in Alcohol Use Disorder

NCT06985927 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2025-05-28
Last updated
2026-08-05

Condition(s) studied

Alcohol Use Disorder

Investigational drug(s) / intervention(s)

psychotherapeutic sessions

psychotherapeutic sessions: Analysis of effect of psychotherapeutic sessions based on self-concept and autobiographical memory on alcohol addiction

Study summary

This study has two objectives. First, to evaluate the effectiveness of psychotherapy sessions based on self-concept and autobiographical memory in patients suffering from alcohol use disorders (AUD). Second, investigate the relationship between drinking identity and AUD. These objectives will be investigated according to a longitudinal design.

In this study, the drinking identity is evaluated on its implicit dimension and on its explicit dimension. Levels of alcohol use and dependence are assessed by the amount and frequency of drinking, the duration of abstinence, and the intensity of AUD symptoms. These assessments consist three visits: on the day of inclusion, then at three months and six months after the first visit. The psychotherapy sessions consist of four individual sessions. They are inspired by the Social Identity Mapping in Addiction Recovery (SIM-AR) by Beckwith et al. (2019), combined with autobiographical reasoning exercises.

Patients with an AUD, participants in the study, are recruited from the addiction department of the Etablissement Public de Santé Mentale de la Marne. To investigate the effects of individual psychotherapy sessions, two groups of patients are constituted randomly. The first group will have four psychotherapy sessions between the first visit and the second vist. The second group will not follow psychotherapy sessions but will benefit from the usual addiction treatments.

The first hypothesis is that patients who have completed the psychotherapy sessions will have lower alcohol consumption (frequency, quantities, peaks) and symptoms of AUD (cravings, drinking refusal self-efficacy and feeling of recovery) than those who have not benefited from the program.

The second hypothesis is that implicit and explicit levels of drinking identity will predict alcohol consumption (frequencies, quantities, peaks) and symptoms of dependence (cravings, drinking refusal self-efficacy and feeling of recovery) for all participants.

Eligibility

Sex
ALL
Min age
24 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Patients over 24 years old, men or women * Having a diagnosis of alcohol use disorder according to DSM-5 criteria * Being a native French speaker * Patients enrolled in the national healthcare insurance program * Consenting to participate to the study Exclusion Criteria: * A diagnosis of current non-stabilized psychiatric disorders according to DSM-5 criteria * The presence of another substance use disorder, except for tobacco dependence * The presence of any intellectual disability, of pervasive developmental disorders * The presence of any neurological disorder or any other disorder affecting the central nervous system including neurological complications of alcoholism * A sensorial impairment uncorrected (visual and/or hearing)

Primary outcome measure(s)

  • Severity of alcohol use disorder — Day 0, to 3 months, to 6 months
    The Alcohol Use Disorder Inventory Test (AUDIT). The AUDIT is self-administered questionnaire consists of 10 items designed to identify the risk of the presence of an alcohol use disorder with or without dependence. Items 1 to 6 assess the presence of an alcohol use disorder, and items 7 to 10 assess problems associated with the participant's drinking pattern

Trial sites (1)

FacilityCityRegionStatus
Chu Reims Reims France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06985927 on ClinicalTrials.gov ↗ ← All trials in France